DE1543522A1 - Therapeutically effective acylaminophenol alkanols and processes for their preparation - Google Patents
Therapeutically effective acylaminophenol alkanols and processes for their preparationInfo
- Publication number
- DE1543522A1 DE1543522A1 DE1966D0050562 DED0050562A DE1543522A1 DE 1543522 A1 DE1543522 A1 DE 1543522A1 DE 1966D0050562 DE1966D0050562 DE 1966D0050562 DE D0050562 A DED0050562 A DE D0050562A DE 1543522 A1 DE1543522 A1 DE 1543522A1
- Authority
- DE
- Germany
- Prior art keywords
- hydroxyphenyl
- aminoethanol
- acid
- amines
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
Therapeutisch wirksame Acylaminophenolalkanole und Verfahren zu ihrer HerstellungTherapeutically effective acylaminophenol alkanols and processes for their preparation
Die Erfindung betrifft Acylaminophenolalkanole der allgemeinen FormelThe invention relates to acylaminophenol alkanols of the general formula
CH - CH - NH - Ac, ι tCH - CH - NH - Ac, ι t
OH REAR
(D(D
in der R Wasserstoff oder niederes Alkyl mit ein bis vier Kohlenstoffatomen und Ac den Acylrest einer aliphatischen gesättigten oder ungesättigten Mono- oder Dicarbonsäure, einer aromatischen oder heterocyclischen oder einer komplexeren organischen Säure mit gegebenenfalls physiologischer Eigenwirkung, wie beispielsweise Theophyllinessigsäure, bedeuten. Außerdem bezieht sich die Erfindung auf ein Verfahren zur Herstellung solcher Ac ylaminophenolalkanoIe.in which R is hydrogen or lower alkyl with one to four carbon atoms and Ac is the acyl radical of an aliphatic saturated or unsaturated mono- or dicarboxylic acid, an aromatic or heterocyclic acid or a more complex organic acid with optionally physiological intrinsic effect, such as theophyllinetic acid, mean. Also relates the invention relates to a process for the preparation of such Ac ylaminophenolalkanoIe.
909836/U92909836 / U92
Es ist bekannt, daß therapeutisch wirksame Hydroxyphenylalkanolamine im Organismus ziemlich schnell zu unwirksamen Verbindungen abgebaut werden. In vielen Fällen ist der rasche Abbau erwünscht. Es gibt aber Kreislauferkrankungen, die einer Therapie mit weniger schnell abklingenden Pharmaka bedürfen.It is known that therapeutically effective hydroxyphenylalkanolamines are broken down into ineffective compounds fairly quickly in the organism. In many cases it is rapid dismantling is desirable. But there are circulatory diseases that require therapy with less rapidly decaying pharmaceuticals.
Es wurde nun gefunden, daß die bisher unbekannten Verbindungen vom Typ IIt has now been found that the previously unknown compounds of type I.
- Cii - CiI - NH - Ac,- Cii - CiI - NH - Ac,
f If I
OH IiOH II
wobei K Wasserstoff oder niederes Alkyl mit ein bis vier Kohlenstoffatomen und Ac einen Acylrest bedeuten, für eine solche Therapie hervorragend geeignet sind. So ist z.B. das N-Acetyl-l-(31-hydroxyphenyl)-2-aminoäthanol zwar im Tierversuch an der Katze oral und parenteral im Gegensatz zu l-(3l-Hydroxyphenyl)-2-aminoäthanol praktisch nicht pressorisch wirksam. Es war daher überraschend, daß N-Acetyl-l-(3·-hydroxyphenyl)-2-aminoäthanol im Schellongtest am Menschen nach oraler Gabe bestimmte hypotone W Zustände sehr günstig beeinflußte; therapieresistende iiypotoniker ließen schon 24 bis 36 Stunden nach Beginn der Behandlung eine Kreislaufstabilisierung erkennen.where K is hydrogen or lower alkyl with one to four carbon atoms and Ac is an acyl radical, are excellently suited for such a therapy. Thus, for example the N-acetyl-l- (1: 3 -hydroxyphenyl) -2-aminoethanol, although orally in animal experiments in the cat and parenterally in contrast to l- (3 L-hydroxyphenyl) -2-aminoethanol virtually no pressor effect. It was therefore surprising that N-acetyl-l- (3 x hydroxyphenyl) -2-aminoethanol certain in Schellongtest in humans after oral administration hypotonic W affected states very favorable; Therapy-resistant hypotonic patients showed a stabilization of the circulatory system just 24 to 36 hours after the start of treatment.
Von besonderem Vorteil ist, daß die Toxizität der Substanz wesentlich geringer ist als die der verwandten, nicht N-acylierten in der Therapie gebräuchlichen Sympathicomiraetica. It is of particular advantage that the toxicity of the substance is significantly lower than that of the related, not N-acylated sympathicomiraetica commonly used in therapy.
Die bei hervorragender Wirkung auf den Kreislauf gegenüber bekannten Verbindungen erhöhte Verträglichkeit der erfindungsgemäßen Verbindungen bedeutet für die Therapie einen wesentlichen Fortschritt.The increased compatibility of the compounds according to the invention with an excellent effect on the circulation compared to known compounds Connections represent a significant advance in therapy.
909836/U92909836 / U92
Diese Verbindungen werden erfindungsgemäß dadurch hergestellt, daß man Amine der FormelAccording to the invention, these compounds are prepared by using amines of the formula
- CHOH - CH - NII0 (II),- CHOH - CH - NII 0 (II),
1 Λ . 1 Λ .
wobei it die für Formel (I) angegebene Bedeutung hat, oder deren Säureadditionssalze in an sich bekannter Weise mit reaktionsfähigen Derivaten der genannten Carbonsäuren v/ie Halogeniden, Anhydriden oder Estern umsetzt, oder daß man die Amine der Formel (II) mit entsprechenden Carbonsauren unter Zusatz wasserabspaltender Mittel, wie beispielsweise Carbonyldiimidazol oder üicyclohexylcarbodiimid, oder bei erhöhter Temperatur zur Reaktion bringt.where it has the meaning given for formula (I), or their acid addition salts in a manner known per se with reactive derivatives of the carboxylic acids mentioned v / ie converting halides, anhydrides or esters, or that the amines of the formula (II) are reacted with corresponding carboxylic acids with the addition of dehydrating agents, such as, for example Carbonyldiimidazole or üicyclohexylcarbodiimid, or reacts at an elevated temperature.
üu den erfindungsgemäß umzusetzenden Aminen gehören beispielsweise JL-(3f-Hydroxyphenyl)-2-aminoäthanol und m-Hydroxy-norephedrin. Als Säurehalogenide finden unter anderen Acetyl-, butyryl-, Benzoyl- und Nicotinoylchiorid, aber auch PropionylbroBiid, Verwendung. Im Rahmen der. Erfindung zu verwendende Anhydride sind beispielsweise Essig-, Bernstein-, Malein-, Glutar- und Benzoesäureanhydrid. Als Ester können Propion-, Benzoe-, Nicotin-, Pivalin-, Chinolin-2-carbon- oder Theophyllin-7-essigsäuremethyl- bzw, äthylester und viele andere eingesetzt werden.The amines to be reacted according to the invention include, for example, JL- (3 f -hydroxyphenyl) -2-aminoethanol and m-hydroxy-norephedrine. Acetyl, butyryl, benzoyl and nicotinoyl chloride, but also propionyl bromide, are used as acid halides. As part of the. Anhydrides to be used in the invention are, for example, acetic, succinic, maleic, glutaric and benzoic anhydrides. As esters, propionic, benzoin, nicotine, pivaline, quinoline-2-carbon or theophylline-7-acetic acid methyl or ethyl ester and many others can be used.
Bei der Umsetzung der Säurehalogenide oder Anhydride in Pyridinlösung können statt der Amine der Formel (II) auch deren Säureadditionssalze wie Hydrochloride oder -bromide zur Reaktion gebracht werden. Bei der Umsetzung von Carbonsäureestern wird eur quantitativen Umsetzung vorzugsweise ein Überschuß an Ester eingesetzt. Setzt man When the acid halides or anhydrides are reacted in pyridine solution, their acid addition salts, such as hydrochlorides or bromides, can also be reacted instead of the amines of the formula (II). When converting carboxylic acid esters, an excess of ester is preferably used for quantitative conversion. If you set
909836/U92 bad original909836 / U92 bad original
die Amine dagegen mit Säurehalogeniden um, so ist zur Erzielung einheitlicher Reaktionsprodukte das Arbeiten mit molaren Mengen in der Kälte zweckmäßig. Die Kondensation von Aminen mit Carbonsäuren führt man zweckmäßig in inerten Lösungsmitteln durch, die mit V/asser nicht mischbar sind, und führt das Reaktionswasser durch azeotrope Destillation ab. Die Kondensation mit Hilfe von Dicyclohexylcarbodiimid wird in Alkoholen, Methylenchlorid, Tetrahydrofuran, Pyridin oder anderen Lösungsmitteln vorgenommen.the amines, on the other hand, with acid halides, then for To achieve uniform reaction products, it is advisable to work with molar quantities in the cold. The condensation of amines with carboxylic acids are expediently carried out in inert solvents, those with water are not are miscible, and removes the water of reaction by azeotropic distillation. The condensation with the help of dicyclohexylcarbodiimide is in alcohols, methylene chloride, tetrahydrofuran, pyridine or other solvents performed.
Die Herstellung der erfindungsgemäßen Verbindungen wird in den nachstehenden Beispielen näher erläutert.The preparation of the compounds according to the invention is explained in more detail in the examples below.
15,3 g 1-(3·-Hydroxyphenyl)-2-aminoäthanol wurden in 150 ml Pyridin gelöst. Unter Rühren und Eiskühlung wurden in 20 Minuten 12,1 g Pivaloylchlorid zugetropft. Es wurde noch zwei Stunden bei 25° C gerührt und dann im Vakuum zur Trockne gebracht. Der Rückstand wurde mit 0,05 Mol Soda und 25 ml Wasser durchgearbeitet und erneut zur Trockne gebracht, worauf dem Rückstand das gebildete Amid mit Alkohol entzogen wurde. Zur Abtrennung nicht umgesetzter Ausgangsverbindung wurde der Eindampfrückstand in n-Butanol gelöst und mehrfach mit Phosphat-Puffer (pH 8) ausgeschüttelt. Die im Butanol enthaltene Substanz wurde aus Essigester umkristallisiert und ergab 11,8 g (50 % d. Th.) N-Pivaloyl-l-(3*-hydroxyphenyl)-2-aminoäthanol in Form weißer Kristalle vom Schmelzpunkt 115 bis 117° C, die sich als dünnschichtchromatographisch einheitlich erwiesen.15.3 g of 1- (3 · -Hydroxyphenyl) -2-aminoethanol were in 150 ml of pyridine dissolved. While stirring and cooling with ice, 12.1 g of pivaloyl chloride were added dropwise over the course of 20 minutes. It was Stirred for a further two hours at 25 ° C. and then brought to dryness in vacuo. The residue was with 0.05 mol Soda and 25 ml of water worked through and again brought to dryness, whereupon the residue formed Amide was withdrawn with alcohol. The evaporation residue was used to separate off unreacted starting compound Dissolved in n-butanol and repeatedly with phosphate buffer (pH 8) shaken out. The substance contained in the butanol was recrystallized from ethyl acetate and resulted 11.8 g (50% of theory) N-pivaloyl-1- (3 * -hydroxyphenyl) -2-aminoethanol in the form of white crystals with a melting point of 115 to 117 ° C, which can be found by thin-layer chromatography consistently proven.
ClAeN03 - 237'3 berechnet " 5'93 * C lAe N0 3 - 237 ' 3 calculated " 5 ' 93 *
"gefunden - 5,95 % "found - 5.95 %
8AD ORIGINAL 909836/U928AD ORIGINAL 909836 / U92
56, t) g l-(3*-Hydroxyphenyl)-2-aminoäthanol-hydrochlorid wurden in 150 ml Pyridin gelöst und unter Kühren bei 200C innerhalb zwei Stunden 30,ο g Essigsäureanhydrid zugetropft. Nach Stehen über Nacht wurde zur Trockne eingeengt, der Rückstand mit 31,8 g wasserfreier Soda und 100 ml Wasser gelöst und erneut eingedampft. Der Rückstand wurde dreimal mit 250 ml Isopropanol extrahiert; die vereinigten Extrakte ergaben.nach Eindampfen 52,4 g festen Rückstand. Dieser wurde zweimal aus Isopropanol umkristallisiert und ergab 31 g (52 % d. Th.) dünnschichtchromatographisch einheitliches N-Acetyl-1-(3f-hydroxyphenyl)-2-aminoäthanol vom Schmelzpunkt 113 bis 119° C.56, t) g l- (3 * hydroxyphenyl) -2-aminoethanol hydrochloride was dissolved in 150 ml of pyridine and added dropwise under Kühren at 20 0 C over two hours 30 ο g of acetic anhydride. After standing overnight, the mixture was concentrated to dryness, the residue was dissolved with 31.8 g of anhydrous soda and 100 ml of water and again evaporated. The residue was extracted three times with 250 ml of isopropanol; the combined extracts yielded 52.4 g of solid residue after evaporation. This was recrystallized twice from isopropanol and gave 31 g (52 % of theory ) N-acetyl-1- (3 f -hydroxyphenyl) -2-aminoethanol with a melting point of 113 ° to 119 ° C., which was uniform by thin layer chromatography.
Cx0H13NÜ3 - 190'2 . »berechnet = 7'1β % C x0 H 13 NÜ 3 - 190 ' 2 . »Calculated = 7 ' 1β %
gefunden " 7'0β % found " 7 ' 0β %
16,4 g l-(3t-Hydroxyphenyl)-2-aminoäthanol-monohydrat wurden in 35 g Propionsäurepropylester 24 Stunden unter Rückfluß gerührt. Anschließend wurde im Vakuum zur Trockne eingeengt. Der Rückstand wurde aus Isopropanol-Essigester umkristallisiert. Man erhielt 12,1 g (58 % d. Th.) N-Propionyl-l-(3'-hydroxyphenyl)-2-aminoäthanol vom Schmelzpunkt 112 bis 114° C.16.4 g of 1- (3 t -hydroxyphenyl) -2-aminoethanol monohydrate were stirred under reflux in 35 g of propionate for 24 hours. It was then concentrated to dryness in vacuo. The residue was recrystallized from isopropanol / ethyl acetate. 12.1 g (58 % of theory ) of N-propionyl-1- (3'-hydroxyphenyl) -2-aminoethanol with a melting point of 112 ° to 114 ° C. were obtained.
ClAöNÜ3 - 2Ü9>25 »berechnet " 6'69 % C LAoE NÜ 3 - 2Ü9> 25 "calculated" 6 '69%
gefunden = 6'68 -found = 6 '68 -
BAD ORIGINAL 90 9836/U92 BATH ORIGINAL 90 9836 / U92
1,67 g l-(3l-Hydroxyphenyl)-2-aminopiOpanoi wurden mit 20 ml Essigsäure-n-butylester 12 Stunden unter Uückfluß erhitzt. Nach Einengen zur Trockne wurde an Kieselgel mit Benzol/Methanol (4 + 1) chromatographiert. Die Hauptfraktion ist dünnschichtchroüiatographisch einheitlich und ergab nach Kristallisation aus Aceton/iither 0,88g (42 1Jo d. Th. ).N-Acety 1-1-(3'-hydroxyphenyl)-2-aminopropanol vom Schmelzpunkt 115 bis llö° C.1.67 g of l- (3 l -hydroxyphenyl) -2-aminopiOpanoi were refluxed with 20 ml of n-butyl acetate for 12 hours. After concentration to dryness, it was chromatographed on silica gel with benzene / methanol (4 + 1). The main fraction is dünnschichtchroüiatographisch uniform and gave after crystallization from acetone / (d 1 42 Jo. Th.) Iither 0.88 g .N-acetyl-1-1- (3'-hydroxyphenyl) -2-aminopropanol from the melting point to 115 ° C llö .
clA5NO3 = 2Ο9'ύ berechnet " ö'69 * c lA5 NO 3 = 2Ο9 ' ύ calculated " ö ' 69 *
gefunden ~ ü'52 % found ~ u '52%
8,55 g l-(3f-iiydroxyphenyi)-2-aminoäthanol-monohydrat wurden in 100 ml Aceton gelöst und mit ö g .bernsteinsäureanhydrid, gelöst in iüO ml Aceton, vez*mischt. Nacn einstundigem stehen wurde die Mischung noch jO Minuten zum xtückflUio erhitzt und dann zur TrocKne gebracht. Der ölige liückstand kristallisierte beim Anreiben mit JEssigsäureäthylester. Zur Analyse wurde nochmals aus Aceton umkristallisiert. Ausbeute: 12,1 g (96 % d. Th.) N-Succinyl-l-(3l-hydroxyphenyl)-2-aminoäthanol vom Schmelzpunkt 133 bis 134° C in Form weißer Kristalle, die in Wasser, Methanol und Äthanol leicht löslich waren.8.55 g of l- (3 f -iiydroxyphenyi) -2-aminoethanol monohydrate were dissolved in 100 ml of acetone and mixed with 6 g of succinic anhydride dissolved in 10 ml of acetone. After standing for one hour, the mixture was heated to the reflux for a further 10 minutes and then brought to dryness. The oily residue crystallized on trituration with ethyl acetate. For analysis, it was recrystallized again from acetone. Yield: 12.1 g (96 % of theory ) of N-succinyl-l- (3 l -hydroxyphenyl) -2-aminoethanol with a melting point of 133 ° to 134 ° C. in the form of white crystals that dissolve easily in water, methanol and ethanol were soluble.
C12H15NO5 = 25ΰ'3 berechnet = 5'5^ * - C 12 H 15 NO 5 = 25ΰ ' 3 calculated = 5 ' 5 ^ * -
gefunden " 5,^%found "5, ^%
In gleicher Weise wie in Beispiel 5 wurden 17,1 g 1-(ö*-Hydroxyphenyl)-2-aminoäthanol-monohydrat mit 9,8 g Maleinsäureanhydrid umgesetzt. Manferistallisierte aus «!ethanol um und erhielt 12,1 g N-Maleinyl-l-(3'-hydroxyphenyl)-2-aminoäthanol vom Schmelzpunkt 181 bis 1Ö3° C (Zers.)o Die Substanz löste sich in niederen Alkoholen und wässriger Bicarbonatlösung.In the same way as in Example 5, 17.1 g of 1- ( δ * -hydroxyphenyl) -2-aminoethanol monohydrate were reacted with 9.8 g of maleic anhydride. Manferistallized from "! Ethanol and obtained 12.1 g of N-maleinyl-1- (3'-hydroxyphenyl) -2-aminoethanol with a melting point of 181 to 13 ° C (decomp.). The substance dissolved in lower alcohols and aqueous bicarbonate solution .
909836/U92 ^I£909836 / U92 ^ I £
C12HiaNO5 - 251'2 »berechnet " 5'58 % C 12 H ia NO 5 - 251 ' 2 »calculated " 5 ' 58 %
gefunden- * δ,4β % Found- * δ, 4β%
17,1 g 1-(3*-Hydroxyphenyl)-2-aminoäthanol-monohydrat wurden mit 50 g Nicotinsäuremethylester verschmolzen und vier Stunden bei 160 C gerührt. Dann wurde überschüssiger Nicotinsäureester weitgehend im Vakuum abdestilliert. Der Rückstand wurde in 250 ml Wasser gelöst, dreimal mit Äther ausgeschüttelt und erneut zur Trockne gebracht. Der ftindampfrücfcstand wurde an Kieselgel mit Benzol/ Methanol (4+1) chromatographiert und ergab als Hauptfraktion 12,5 g (48 % d. Th.) N-Nicotinoyl-l-(3·-hydroxyphenyl )-2-aminoäthanol vom Schmelzpunkt 146 bis 148° C1 das zur analyse aus Äthanol/Äther umkristallisiert wurde.17.1 g of 1- (3 * -hydroxyphenyl) -2-aminoethanol monohydrate were melted with 50 g of methyl nicotinate and stirred at 160 ° C. for four hours. Excess nicotinic acid ester was then largely distilled off in vacuo. The residue was dissolved in 250 ml of water, extracted three times with ether and again brought to dryness. The vapor residue was chromatographed on silica gel with benzene / methanol (4 + 1) and gave the main fraction 12.5 g (48 % of theory ) of N-nicotinoyl-1- (3-hydroxyphenyl) -2-aminoethanol with a melting point of 146 up to 148 ° C 1 which was recrystallized from ethanol / ether for analysis.
ClAA°3 - 258'3 »berechnet " 10'85 % C LAA ° 3 - 258 ' 3 »calculated" 10 ' 85 %
N - lü,5ii % N - lü, 5ii %
gefundenfound
15,b g 1-(3*-Hydroxyphenyl)-2-aminoäthanol und 25,2 g Theophyllin-7-essigsäuremethylester wurden im llundkolben geschmolzen und bei aufgesetztem Steigrohr zwei Stunden auf 120 bis 125° C gehalten. Nach Erkalten wurde der kristalline Kuchen aus reichlich Methanol umgelöst. Es wurden 22,7 g (61 % d. Th.) N-Theophyllin-7-acetyll-(3t-hydroxyphenyl)-2-aminoäthanol in Form weißer, dünnschichtchromatographisch einheitlicher Kristalle vom Schmelzpunkt 210 bis 212° C erhalten.15, bg 1- (3 * -hydroxyphenyl) -2-aminoethanol and 25.2 g of theophylline-7-acetic acid methyl ester were melted in the bottom flask and kept at 120 to 125 ° C. for two hours with the riser tube attached. After cooling, the crystalline cake was redissolved from copious amounts of methanol. There were 22.7 g (61% d. Th.) N-theophylline-7-acetyll- (t 3 -hydroxyphenyl) -2-aminoethanol in a white form, obtained by thin layer chromatography uniform crystals of melting point 210 to 212 ° C.
C17H19N5°5 * 373'4 »berechnet " 18'78 % C 17 H 19 N 5 ° 5 * 373 ' 4 »calculated" 18 ' 78 %
Viunden - ".« *Viunden - ".« *
909836/1492909836/1492
8,55 g 1-(.3·-Hydroxyphenyl)-2-aminoäthanol-monohydrat und 6,1 g Benzoesäure wurden unter Zusatz von 1 Tropfen konz. Schwefelsäure in 200 ml Xylol unter Zwischenschaltung eines Wasserabscheiders am Rückfluß gekocht. Nach Abscheidung von ca. 2 ml Wasser war die Reaktion beendet. Man zog Xylol im Vakuum weitgehend ab, nahm in Methylenchlorid auf, wusch dreimal mit Wasser und engte zur Trockne ein. Der Rückstand wurde aus Essigsäureäthylester umkristallisiert. Man erhielt 11,4 g N-Benzoyll-(3·-hydroxyphenyl)-2-aminoäthanol vom Schmelzpunkt 149 bis 150° C. Die Substanz bildete farblose Kristalle, die in Wasser, Säuren und Alkalien unlöslich und in niederen Alkoholen leicht löslich waren.8.55 g of 1 - (. 3 · -Hydroxyphenyl) -2-aminoethanol monohydrate and 6.1 g of benzoic acid were concentrated with the addition of 1 drop. Sulfuric acid in 200 ml of xylene with the interposition boiled under reflux in a water separator. After about 2 ml of water had separated off, the reaction was complete. Most of the xylene was removed in vacuo, taken up in methylene chloride, washed three times with water and concentrated Dry up. The residue was recrystallized from ethyl acetate. 11.4 g of N-benzoyl- (3 · hydroxyphenyl) -2-aminoethanol were obtained from a melting point of 149 to 150 ° C. The substance formed colorless crystals, which were insoluble in water, acids and alkalis and easily soluble in lower alcohols.
CI5H15NO3 - 257·3 . »berechnet " 5'45 % C 15 H 15 NO 3 - 257 x 3 . »Calculated" 5 '45 %
»gefunden- - 5,24 *»Found- - 5.24 *
15,3 g 1-(3'-Hydroxyphenyl)-2-aminoäthanol und 12,2 g Benzoesäure wurden in 100 ml Pyridin gelöst, und bei -10° C wurden 20,6 g Dicyclohexylcarbodiimid portionsweise eingetragen. Im Verlauf von fünf Stunden ließ man auf Raumtemperatur erwärmen und saugte vom Dicyclohexylharnstoff ab. Das FiItrat wurde im Vakuum eingeengt und der Rückstand aus Essigester umkristallisiert. Man erhielt in 72 %iger Ausbeute N-Benzoyl-1-(3·-hydroxyphenyl)-2-aminoäthanol, das in Schmelzpunkt, Mischschmelzpunkt und Analyse mit der gemäß Beispiel 9 erhaltenen Substanz identisch war.15.3 g of 1- (3'-hydroxyphenyl) -2-aminoethanol and 12.2 g Benzoic acid was dissolved in 100 ml of pyridine, and at -10 ° C. 20.6 g of dicyclohexylcarbodiimide were added in portions registered. The mixture was allowed to warm to room temperature over the course of five hours and the dicyclohexylurea was sucked off away. The filtrate was concentrated in vacuo and the residue was recrystallized from ethyl acetate. One received in 72% yield N-benzoyl-1- (3 · hydroxyphenyl) -2-aminoethanol, that in melting point, mixed melting point and analysis with the substance obtained according to Example 9 was identical.
Zur Erfindung gehört alles dasjenige, was in der Beschreibung enthalten ist einschließlich dessen, was abweichend von den konkreten Ausführungsbeispielen für den Fachmann naheliegt.The invention includes everything that is contained in the description, including everything that deviates of the specific exemplary embodiments are obvious to the person skilled in the art.
Patentansprüche: 909836/U92 Claims: 909836 / U92
BAD ORIGINALBATH ORIGINAL
Claims (15)
:ie Unterlagen (Art. 7 sn /**.2 N-.: t..te,. ousÄnderunflsge..Y.4.9. um»}9 0983 6 / U92
: ie documents (Art. 7 sn /**.2 N- .: t .. te ,. ousAnderunflsge .. Y .4.9. at »}
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE1966D0050562 DE1543522B2 (en) | 1966-07-14 | 1966-07-14 | ACYLAMINOPHENOL ALCANOLS, THE PROCESS FOR THEIR MANUFACTURING AND PHARMACEUTICAL AGENTS CONTAINING THESE ACYLAMINOPHENOL ALCANOLS |
DE19671593828 DE1593828A1 (en) | 1966-07-14 | 1967-05-16 | Process for the preparation of therapeutically active acylaminophenolalkanols |
DE19671593834 DE1593834A1 (en) | 1966-07-14 | 1967-05-26 | Process for the preparation of therapeutically active acylaminophenolalkanols |
CH829367A CH523224A (en) | 1966-07-14 | 1967-06-12 | Acylaminophenylalkanols - used to stabilize the blood circulation |
AT560267A AT273932B (en) | 1966-07-14 | 1967-06-16 | Process for the preparation of new 1- (3'-hydroxyphenyl) -2-acylaminoalkanolen- (1) and their O <1> -mono- or O, O-diacyl derivatives |
SE904267A SE335541B (en) | 1966-07-14 | 1967-06-22 | |
DK358267A DK125198B (en) | 1966-07-14 | 1967-07-11 | Analogous process for the preparation of therapeutically effective acylaminophenol alkanols. |
GB3211867A GB1137596A (en) | 1966-07-14 | 1967-07-12 | Therapeutically active acylamino-phenol-alkanols |
FR114197A FR1537803A (en) | 1966-07-14 | 1967-07-13 | Process for making acylaminophenolalkanols |
ES343008A ES343008A1 (en) | 1966-07-14 | 1967-07-13 | Procedure for preparing acilaninofenolalcanoles. (Machine-translation by Google Translate, not legally binding) |
NL6709789A NL6709789A (en) | 1966-07-14 | 1967-07-14 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE1966D0050562 DE1543522B2 (en) | 1966-07-14 | 1966-07-14 | ACYLAMINOPHENOL ALCANOLS, THE PROCESS FOR THEIR MANUFACTURING AND PHARMACEUTICAL AGENTS CONTAINING THESE ACYLAMINOPHENOL ALCANOLS |
DED0053088 | 1967-05-16 | ||
DED0053177 | 1967-05-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
DE1543522A1 true DE1543522A1 (en) | 1969-09-04 |
DE1543522B2 DE1543522B2 (en) | 1976-05-06 |
Family
ID=27209864
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE1966D0050562 Granted DE1543522B2 (en) | 1966-07-14 | 1966-07-14 | ACYLAMINOPHENOL ALCANOLS, THE PROCESS FOR THEIR MANUFACTURING AND PHARMACEUTICAL AGENTS CONTAINING THESE ACYLAMINOPHENOL ALCANOLS |
DE19671593828 Pending DE1593828A1 (en) | 1966-07-14 | 1967-05-16 | Process for the preparation of therapeutically active acylaminophenolalkanols |
DE19671593834 Pending DE1593834A1 (en) | 1966-07-14 | 1967-05-26 | Process for the preparation of therapeutically active acylaminophenolalkanols |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE19671593828 Pending DE1593828A1 (en) | 1966-07-14 | 1967-05-16 | Process for the preparation of therapeutically active acylaminophenolalkanols |
DE19671593834 Pending DE1593834A1 (en) | 1966-07-14 | 1967-05-26 | Process for the preparation of therapeutically active acylaminophenolalkanols |
Country Status (7)
Country | Link |
---|---|
AT (1) | AT273932B (en) |
CH (1) | CH523224A (en) |
DE (3) | DE1543522B2 (en) |
DK (1) | DK125198B (en) |
GB (1) | GB1137596A (en) |
NL (1) | NL6709789A (en) |
SE (1) | SE335541B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6210048A (en) * | 1985-07-04 | 1987-01-19 | Microbial Chem Res Found | Novel physiologically active substance mh435 |
-
1966
- 1966-07-14 DE DE1966D0050562 patent/DE1543522B2/en active Granted
-
1967
- 1967-05-16 DE DE19671593828 patent/DE1593828A1/en active Pending
- 1967-05-26 DE DE19671593834 patent/DE1593834A1/en active Pending
- 1967-06-12 CH CH829367A patent/CH523224A/en not_active IP Right Cessation
- 1967-06-16 AT AT560267A patent/AT273932B/en active
- 1967-06-22 SE SE904267A patent/SE335541B/xx unknown
- 1967-07-11 DK DK358267A patent/DK125198B/en unknown
- 1967-07-12 GB GB3211867A patent/GB1137596A/en not_active Expired
- 1967-07-14 NL NL6709789A patent/NL6709789A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
SE335541B (en) | 1971-06-01 |
AT273932B (en) | 1969-08-25 |
DE1593834A1 (en) | 1971-02-25 |
GB1137596A (en) | 1968-12-27 |
DE1543522B2 (en) | 1976-05-06 |
CH523224A (en) | 1972-05-31 |
DE1593828A1 (en) | 1970-10-29 |
DK125198B (en) | 1973-01-15 |
NL6709789A (en) | 1968-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE1930818C3 (en) | 1-Substituted 3- or 4-aroylpiperidines, process for their preparation and their use | |
DE2635853A1 (en) | PYRROLIDINE-2-ON DERIVATIVES, THE PROCESS FOR THEIR MANUFACTURING AND THE MEDICINAL PRODUCT CONTAINING THEY | |
DE2265169B2 (en) | Ethyl Vincaminate, Manufacturing Processes and Pharmaceutical Agents | |
CH392542A (en) | Process for the preparation of basic amides | |
DE2446100C3 (en) | Phenoxyalkanecarboxamides of thiazolidinecarboxylic acids, process for their preparation and pharmaceuticals | |
CH472407A (en) | Process for the preparation of new 2-benzyl-1,3,4,9b-tetrahydro-2H-indeno (1,2-c) pyridine derivatives | |
DE2748466A1 (en) | 4A-ARYLOCTAHYDRO-1H-2-PYRINDINE | |
DE1543522A1 (en) | Therapeutically effective acylaminophenol alkanols and processes for their preparation | |
DE2513136C3 (en) | N- (1-Benzylpiperid-4-yl) -benzamides, process for their preparation and pharmaceutical preparations containing them | |
DE2500808B2 (en) | 4-CYCLOPROPYLMETHYLENOXY-3-CHLOROPHENYL ACID ACID AND THEIR SALES, PROCESS FOR THEIR MANUFACTURING AND MEDICINAL PRODUCTS CONTAINING THESE | |
EP0760367A2 (en) | Process for the manufacture of 4-acylamino-2,2,6,6-tetramethylpiperidines | |
DE2122070A1 (en) | 1 Veratryl 4 methyl 5 ethyl 7,8 dimethoxy 2,3 diazabicyclo square brackets to 5,4,0 square brackets to undeca pentaen (1,3,6,8,10) and its use | |
DE2639181C3 (en) | 2,4,5-Trimethyl-thieno [3,2-fj morphan, process for its preparation and medicament containing it | |
DE2404924A1 (en) | ERGOLINE DERIVATIVES | |
DE1543522C3 (en) | Acylaminophenol alkanols, processes for their preparation and pharmaceutical compositions containing these acylaminophenol alkanols | |
DE2021747A1 (en) | Process for the preparation of new heterocyclic compounds | |
DE1695580C (en) | Quaternary compounds of benzil acid beta piperidino ethyl ester and a process for their preparation | |
DE2312256C3 (en) | 5-pyrazole acetic acid derivatives, processes for their preparation and pharmaceutical compositions containing them | |
DE1620190C (en) | 4- (2-Carbo-alpha-glyceryloxyphenylamino) -8-chloroquinoline, its salts and a process for their preparation | |
DE2523208C3 (en) | Thienylacetic acid esters, a process for their preparation and pharmaceuticals | |
AT266833B (en) | Process for the preparation of new 1- [4-oxo-4- (4-fluoro-phenyl) -butyl] -piperidines and their acid addition salts | |
DE1620556C (en) | 1 Cyclohexylbarbituric acid derivatives | |
DE1470205C (en) | 5-Nitropyrrole derivatives and process for their preparation | |
DE1418540C (en) | Process for the preparation of 1,3,2 dioxaborolanes or 1,3,2 dioxabonnanes | |
DE2433681A1 (en) | NEW BENZYLOXYSULFAMIDES, THEIR SALTS, METHOD OF MANUFACTURING AND PHARMACEUTICAL COMPOSITIONS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C3 | Grant after two publication steps (3rd publication) | ||
E77 | Valid patent as to the heymanns-index 1977 | ||
EHJ | Ceased/non-payment of the annual fee |